Prospective study analyzed the association between efficacy and adverse events by Atezolizumab immunotherapy and diversity or species of fecal microbiota in advanced /reccurent non-small cell lung cancer patients
Not Applicable
- Conditions
- advanced/reccurent non-small cell lung cancer patients
- Registration Number
- JPRN-UMIN000041822
- Lead Sponsor
- ational Hospital Organization Kyushu Medical Center, Clinical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Inadequate cases judged by doctors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method